Inhibition of HIV-1 replication by the combined action of anti-gp41 single chain antibody and IL-16.
HIV-1 replication is inhibited in T cells transfected with an anti-gp41 single chain antibody (ScFv) or IL-16. These two molecules target totally different events in the HIV-1 replication cycle. The present study shows that HIV-1 replication is inhibited to a substantially greater extent and for a longer duration in cells transfected with both anti-gp41 and IL-16 than with either molecule alone. It is concluded that anti-gp41 and IL-16 act in a synergistic fashion to inhibit HIV-1 replication.
Devadas
Krishnakumar
K
Experimental Medicine Section, Oral Immunity and Infection Branch, Building 30, Room 121, NIDCR, National Institutes of Health, 30 Convent Drive, MSC 4322, Bethesda, MD 20892-4322, USA. devadas@cber.fda.gov
Zhou
Paul
P
Tewari
Deepanker
D
Notkins
Abner Louis
AL
D000914:Antibodies, Viral / Q000494:pharmacology*; D015704:CD4 Antigens / Q000096:biosynthesis; D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D018274:Electroporation; D015700:HIV Envelope Protein gp41 / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019410:Interleukin-16 / Q000494:pharmacology*; D019169:Jurkat Cells; D007700:Kinetics; D013050:Spectrometry, Fluorescence; D013601:T-Lymphocytes / Q000821:virology; D014162:Transfection; D014779:Virus Replication / Q000187:drug effects*
D000914:Antibodies, Viral; D015704:CD4 Antigens; D015700:HIV Envelope Protein gp41; D019410:Interleukin-16